Get started
Author

Kenneth V. Lawson

Observed names: K. Lawson, K. V. Lawson, Kenneth K.V. Lawson, Kenneth Lawson, Kenneth V Lawson, Lawson, Kenneth V.
ORCID: 0000-0001-5094-6337
Observed ORCID: 0000-0001-5094-6337
OpenAlex ID: A5084561236
Discovery of AB680: A Potent and Selective Inhibitor of CD73
2020 · Kenneth V. Lawson, Jaroslaw Kalisiak, et al. · Journal of Medicinal Chemistry · 100
Targeting Metabolism of Extracellular Nucleotides via Inhibition of Ectonucleotidases CD73 and CD39
2020 · Jenna L. Jeffrey, Kenneth V. Lawson, et al. · Journal of Medicinal Chemistry · 91
Discovery of Potent and Selective Non-Nucleotide Small Molecule Inhibitors of CD73
2020 · Joel W. Beatty, Erick A. Lindsey, et al. · Journal of Medicinal Chemistry · 68
Template-constrained macrocyclic peptides prepared from native, unprotected precursors
2013 · Kenneth V. Lawson, Tristan E. Rose, et al. · Proceedings of the National Academy of Sciences · 60
Discovery of Potent and Selective PI3Kγ Inhibitors
2020 · Samuel L. Drew, Rhiannon Thomas-Tran, et al. · Journal of Medicinal Chemistry · 46
PDF
Discovery of Potent and Selective Methylenephosphonic Acid CD73 Inhibitors
2021 · Ehesan U. Sharif, Jaroslaw Kalisiak, et al. · Journal of Medicinal Chemistry · 40
Template-induced macrocycle diversity through large ring-forming alkylations of tryptophan
2013 · Kenneth V. Lawson, Tristan E. Rose, et al. · Tetrahedron · 32
Discovery of Potent and Selective 7-Azaindole Isoindolinone-Based PI3Kγ Inhibitors
2020 · Dillon H. Miles, Xuelei Yan, et al. · ACS Medicinal Chemistry Letters · 24
Large ring-forming alkylations provide facile access to composite macrocycles
2015 · Tristan E. Rose, Kenneth V. Lawson, et al. · Chemical Science · 24
PDF
On the prevalence of bridged macrocyclic pyrroloindolines formed in regiodivergent alkylations of tryptophan
2016 · Tristin E. Rose, Brice H. Curtin, et al. · Chemical Science · 22
PDF
Design, Synthesis, and Structure–Activity Relationship Optimization of Pyrazolopyrimidine Amide Inhibitors of Phosphoinositide 3-Kinase γ (PI3Kγ)
2021 · Guillaume Mata, Dillon H. Miles, et al. · Journal of Medicinal Chemistry · 19
Casdatifan (AB521) is a novel and potent allosteric small molecule inhibitor of protumourigenic HIF‐2α dependent transcription
2025 · Patrick G. Schweickert, Dana Piovesan, et al. · British Journal of Pharmacology · 17
PDF
Synthesis of Diazacalix[8]arene and Triazacalix[12]arene Methyl Ethers via Intramolecular Aryl Amination
2009 · Kenneth V. Lawson, Ashlee C. Barton, et al. · Organic Letters · 12
Stereodivergent Synthesis of the Vicinal Difluorinated Tetralin of Casdatifan Enabled by Ru-Catalyzed Transfer Hydrogenation
2025 · Guillaume Mata, Artur K. Mailyan, et al. · Organic Letters · 11
Synthesis of a designed sesquiterpenoid that forms useful composites with peptides and related oligomers
2010 · Kenneth V. Lawson, Tristan E. Rose, et al. · Tetrahedron Letters · 9
Development of a Scalable Synthesis of Casdatifan (AB521), a Potent, Selective, Clinical-Stage Inhibitor of HIF-2α
2025 · Clayton Hardman, Artur K. Mailyan, et al. · Organic Process Research & Development · 7
Abstract 1756: Discovery and characterization of AB680, a potent and selective small-molecule CD73 inhibitor for cancer immunotherapy
2018 · Kenneth V. Lawson, Lixia Jin, et al. · Cancer Research · 6
Abstract 1206: Discovery and characterization of AB521, a novel, potent, and selective hypoxia-inducible factor (HIF)-2α inhibitor
2021 · Kenneth V. Lawson, Kelsey E. Sivick Gauthier, et al. · Cancer Research · 5
Development of a Scalable Method for Manufacturing the Central Core of CD73 Inhibitor AB680
2020 · Jeremy Fournier, Xuelei Yan, et al. · Organic Process Research & Development · 5
AB680, a potent and selective CD73 small molecule inhibitor, reverses the AMP/adenosine-mediated impairment of immune effector cell activation by immune checkpoint inhibitors
2018 · U. Schindler, A. Becker, et al. · European Journal of Cancer · 4
Abstract A012: Discovery and characterization of Casdatifan (AB521), a clinical-stage, potent, and selective Hypoxia-Inducible Factor (HIF)-2α inhibitor
2024 · Kenneth V. Lawson, Artur Mailyan, et al. · Molecular Cancer Therapeutics · 3
Abstract A002: Targeting hypoxia inducible factor (HIF)-2α with AB521, a novel and potent small molecule HIF-2α inhibitor, for the treatment of clear cell renal cell carcinoma
2023 · Dana Piovesan, Soonweng Cho, et al. · Cancer Research · 3
Discovery of Casdatifan, Part II: A Potent and Orally Bioavailable Inhibitor of Hypoxia Inducible Factor-2α
2026 · Artur K. Mailyan, Guillaume Mata, et al. · Journal of Medicinal Chemistry · 2
Discovery of Casdatifan, Part I: Design and Characterization of Tetrahydroquinoline Inhibitors of Hypoxia-Inducible Factor-2α
2026 · Guillaume Mata, Artur K. Mailyan, et al. · Journal of Medicinal Chemistry · 2
91 (PB079): AB521 (Casdatifan) potently and selectively inhibits Hypoxia-Inducible Factor 2 Alpha (HIF-2α) dependent pro-tumorigenic activity
2024 · P. Schweickert, D. Piovesan, et al. · European Journal of Cancer · 1
Works count: 36
Citation count: 615
H-index: 12
I10-index: 14
Year
Topic
Type